Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This trial will be a pilot study to find out if zoledronic acid improves the response to
chemotherapy in high grade osteosarcoma. In arm A of the study, 40 adult patients will be
randomised into two groups. One group will get standard chemotherapy and the other group will
get Zoledronic acid in addition to chemotherapy. The investigators will assess the
histological necrosis as well as disease status for up to 2 years.
In Arm B, adult patients with relapsed disease or advanced disease who are unable to take any
other therapy and are given only symptomatic care will be given 6 doses of zoledronic acid
and followed up for disease status. This will be to determine the role of zoledronic acid as
a single agent.